Eleven Biotherapeutics

KalVista Pharmaceuticals, based in Cambridge, MA, is dedicated to advancing science to empower individuals living with hereditary angioedema (HAE). Through innovative research and the development of orally delivered small molecule medicines, the company aims to transform the treatment landscape for HAE patients by addressing their unmet needs. With a team of skilled professionals and experienced scientists, KalVista is focused on elevating the standard of care for patients suffering from various diseases, starting with HAE. Their lead product, sebetralstat, represents a potential new oral treatment option designed to enhance the management of this challenging condition. Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website